Loading clinical trials...
Loading clinical trials...
GDM is characterized by decreased insulin sensitivity, decreased insulin secretion, or a combination of both. Women with GDM are at significant risk for overt T2DM later in life, and postpartum insulin sensitivity and secretion in women with GDM has not been quantified, limiting our ability to optimize screening for overt T2DM. In addition, compliance with currently recommended postpartum T2DM screening by OGTT is poor. Quantification of postpartum insulin sensitivity and secretion in women at high risk for T2DM will inform strategies to improve diagnostic strategies. Continuous glucose monitoring (CGM) is a new technology that may be useful to identify women with persistent hyperglycemia. Understanding maternal glycemia and physiology that drives glycemia in the postpartum period is limited. Completion of this study will define postpartum maternal glycemia, quantify insulin secretion versus insulin sensitivity defects, and demonstrate the feasiblity of using continuous glucose monitoring to identify women most at risk for overt T2DM.
Age
18 - 45 years
Sex
FEMALE
Healthy Volunteers
No
University of Alabama at Birmingham
Birmingham, Alabama, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Start Date
September 17, 2021
Primary Completion Date
December 10, 2024
Completion Date
December 10, 2024
Last Updated
December 18, 2024
40
ACTUAL participants
2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor
DIAGNOSTIC_TEST
Lead Sponsor
University of Alabama at Birmingham
Collaborators
NCT06648174
NCT06948825
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions